{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:12Z","timestamp":1785131952943,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008660","name":"Kurozumi Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04210-5","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:42:39Z","timestamp":1776109359000},"page":"204-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab"],"prefix":"10.1007","volume":"124","author":[{"given":"Yusuke","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-7471","authenticated-orcid":false,"given":"Takeshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Urushihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"1","key":"4210_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4210_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808\u201317. https:\/\/doi.org\/10.1182\/bloodadvances.2021005822.","journal-title":"Blood Adv"},{"issue":"4","key":"4210_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. Evidence meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359\u201367. https:\/\/doi.org\/10.1182\/blood.2024024371.","journal-title":"Blood"},{"issue":"1","key":"4210_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61\u201372. https:\/\/doi.org\/10.1002\/cyto.b.21265.","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"4210_CR5","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"issue":"3","key":"4210_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431\u20138. https:\/\/doi.org\/10.3324\/haematol.11080.","journal-title":"Haematologica"},{"issue":"3","key":"4210_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1003032.","journal-title":"J Immunol"},{"issue":"17","key":"4210_CR8","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vall\u00e9e F, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0695.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4210_CR9","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","volume":"12","author":"K Bisht","year":"2023","unstructured":"Bisht K, Fukao T, Chiron M, Richardson P, Atanackovic D, Chini E, et al. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med. 2023;12(20):20332\u201352. https:\/\/doi.org\/10.1002\/cam4.6619.","journal-title":"Cancer Med"},{"key":"4210_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbrc.2020.12.048","volume":"536","author":"HT Lee","year":"2021","unstructured":"Lee HT, Kim Y, Park UB, Jeong TJ, Lee SH, Heo YS. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma. Biochem Biophys Res Commun. 2021;536:26\u201331. https:\/\/doi.org\/10.1016\/j.bbrc.2020.12.048.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"4210_CR11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169235","volume":"102","author":"A Oberle","year":"2017","unstructured":"Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102(9):e368. https:\/\/doi.org\/10.3324\/haematol.2017.169235.","journal-title":"Haematologica"},{"issue":"24","key":"4210_CR12","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1158\/1078-0432.Ccr-17-2027","volume":"23","author":"J Krejcik","year":"2017","unstructured":"Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with Daratumumab. Clin Cancer Res. 2017;23(24):7498\u2013511. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2027.","journal-title":"Clin Cancer Res"},{"issue":"6 Pt 2","key":"4210_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/trf.13150","volume":"55","author":"M Oostendorp","year":"2015","unstructured":"Oostendorp M, van Bueren LJJ, Doshi P, Khan I, Ahmadi T, Parren PW, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555\u201362. https:\/\/doi.org\/10.1111\/trf.13150.","journal-title":"Transfusion"},{"issue":"12","key":"4210_CR14","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/trf.13789","volume":"56","author":"CI Chapuy","year":"2016","unstructured":"Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, et al. International validation of a dithiothreitol (DTT)-based method to resolve the Daratumumab interference with blood compatibility testing. Transfusion. 2016;56(12):2964\u201372. https:\/\/doi.org\/10.1111\/trf.13789.","journal-title":"Transfusion"},{"issue":"6","key":"4210_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","volume":"54","author":"C McCudden","year":"2016","unstructured":"McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, et al. Monitoring multiple myeloma patients treated with Daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095\u2013104. https:\/\/doi.org\/10.1515\/cclm-2015-1031.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"4210_CR16","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00277-021-04634-5","volume":"100","author":"K Sato","year":"2021","unstructured":"Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, et al. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Ann Hematol. 2021;100(12):2989\u201395. https:\/\/doi.org\/10.1007\/s00277-021-04634-5.","journal-title":"Ann Hematol"},{"issue":"4","key":"4210_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/ajcp\/aqab163","volume":"157","author":"A Broijl","year":"2022","unstructured":"Broijl A, de Jong ACM, van Duin M, Sonneveld P, K\u00fchnau J, van der Velden VHJ. VS38c and CD38-multiepitope antibodies provide highly comparable minimal residual disease data in patients with multiple myeloma. Am J Clin Pathol. 2022;157(4):494\u20137. https:\/\/doi.org\/10.1093\/ajcp\/aqab163.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"4210_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"},{"issue":"4","key":"4210_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202. https:\/\/doi.org\/10.1038\/s41591-024-03485-7.","journal-title":"Nat Med"},{"issue":"17","key":"4210_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"6","key":"4210_CR21","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.7150\/thno.38533","volume":"10","author":"L Schriewer","year":"2020","unstructured":"Schriewer L, Sch\u00fctze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, et al. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics. 2020;10(6):2645\u201358. https:\/\/doi.org\/10.7150\/thno.38533.","journal-title":"Theranostics"},{"key":"4210_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1010270","volume":"13","author":"LJ Pape","year":"2022","unstructured":"Pape LJ, Hambach J, Gebhardt AJ, Rissiek B, St\u00e4hler T, Tode N, et al. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under Daratumumab therapy. Front Immunol. 2022;13:1010270. https:\/\/doi.org\/10.3389\/fimmu.2022.1010270.","journal-title":"Front Immunol"},{"key":"4210_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449.","journal-title":"Annu Rev Biochem"},{"key":"4210_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603. https:\/\/doi.org\/10.3389\/fimmu.2017.01603.","journal-title":"Front Immunol"},{"key":"4210_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01182","volume":"10","author":"EY Yang","year":"2020","unstructured":"Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182. https:\/\/doi.org\/10.3389\/fonc.2020.01182.","journal-title":"Front Oncol"},{"issue":"1","key":"4210_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2016.273","volume":"31","author":"T Harada","year":"2017","unstructured":"Harada T, Miki H, Cui Q, Oda A, Amachi R, Teramachi J, et al. Expansion of Th(1)-like V\u03b3(9)V\u03b4(2)T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid. Leukemia. 2017;31(1):258\u201362. https:\/\/doi.org\/10.1038\/leu.2016.273.","journal-title":"Leukemia"},{"issue":"4","key":"4210_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/cyto.b.21961","volume":"100","author":"KT Soh","year":"2021","unstructured":"Soh KT, Tario JD, Hahn T, Hillengass J, McCarthy PL, Wallace PK. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry B Clin Cytom. 2021;100(4):497\u2013508. https:\/\/doi.org\/10.1002\/cyto.b.21961.","journal-title":"Cytometry B Clin Cytom"},{"key":"4210_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20218","author":"A Shameli","year":"2025","unstructured":"Shameli A, Catey T, Woodings V, Koepke O, Fromm JR, Cherian S. Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies. Br J Haematol. 2025. https:\/\/doi.org\/10.1111\/bjh.20218.","journal-title":"Br J Haematol"},{"issue":"7","key":"4210_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959\u201370. https:\/\/doi.org\/10.1182\/blood-2016-03-703439.","journal-title":"Blood"},{"issue":"20","key":"4210_CR30","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","volume":"136","author":"D Ogiya","year":"2020","unstructured":"Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020;136(20):2334\u201345. https:\/\/doi.org\/10.1182\/blood.2019004332.","journal-title":"Blood"},{"issue":"6","key":"4210_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38(6):1323\u201333. https:\/\/doi.org\/10.1038\/s41375-024-02206-w.","journal-title":"Leukemia"},{"issue":"6","key":"4210_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/bjh.20106","volume":"206","author":"W Kuroki","year":"2025","unstructured":"Kuroki W, Kitadate A, Takahashi Y, Iwama S, Yamada M, Kobayashi T, et al. Multiple myeloma with 1q gain\/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression. Br J Haematol. 2025;206(6):1615\u201326. https:\/\/doi.org\/10.1111\/bjh.20106.","journal-title":"Br J Haematol"},{"issue":"1","key":"4210_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;13(1):3750. https:\/\/doi.org\/10.1038\/s41467-022-31430-0.","journal-title":"Nat Commun"},{"issue":"9","key":"4210_CR34","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/leu.2012.80","volume":"26","author":"N Hosen","year":"2012","unstructured":"Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 2012;26(9):2135\u201341. https:\/\/doi.org\/10.1038\/leu.2012.80.","journal-title":"Leukemia"},{"issue":"3","key":"4210_CR35","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","volume":"41","author":"Y Kawano","year":"2012","unstructured":"Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876\u201384. https:\/\/doi.org\/10.3892\/ijo.2012.1545.","journal-title":"Int J Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04210-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04210-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04210-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:37Z","timestamp":1785128677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04210-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4210"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04210-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H. received research funding from Sanofi K.K., and honoraria from Bristol-Myers Squibb, and scholarship funding from Chugai Pharmaceutical Co., Ltd. K.M. received honoraria from Astellas Pharma, Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., AbbVie GK, and Amgen K.K. The other authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: 3842 in Tokushima University Hospital.Informed Consent: Primary samples were obtained from all the patients with written informed consent according to the Declaration of Helsinki.Registry and the Registration No. of the study\/trial: N\/A.Animal Studies: N\/A.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}